PARP Inhibitors in Pancreatic Cancer

Timothy J. Brown; Kim A. Reiss

doi:10.1097/PPO.0000000000000554

PARP Inhibitors in Pancreatic Cancer

Timothy J. Brown, Kim A. Reiss

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.

Original language	English (US)
Pages (from-to)	465-475
Number of pages	11
Journal	Cancer Journal
Volume	27
Issue number	6
DOIs	https://doi.org/10.1097/PPO.0000000000000554
State	Published - Dec 27 2021
Externally published	Yes

Keywords

BRCA
DNA damage repair
homologous recombination repair
pancreatic cancer
PARP inhibitors

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/PPO.0000000000000554

Cite this

@article{c87cd2af1b5c4068beceb42b86bb1cab,

title = "PARP Inhibitors in Pancreatic Cancer",

abstract = "Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.",

keywords = "BRCA, DNA damage repair, homologous recombination repair, pancreatic cancer, PARP inhibitors",

author = "Brown, {Timothy J.} and Reiss, {Kim A.}",

note = "Funding Information: Conflicts of Interest and Source of Funding: Funding was provided by NIH T32CA009679 (to T.J.B.). K.A.R. receives research funding from Clovis Oncology, Bristol-Myers-Squibb, and GlaxoSmithKline. For T.J.B., none were declared. Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",

year = "2021",

month = dec,

day = "27",

doi = "10.1097/PPO.0000000000000554",

language = "English (US)",

volume = "27",

pages = "465--475",

journal = "Cancer Journal",

issn = "1528-9117",

number = "6",

}

TY - JOUR

T1 - PARP Inhibitors in Pancreatic Cancer

AU - Brown, Timothy J.

AU - Reiss, Kim A.

N1 - Funding Information: Conflicts of Interest and Source of Funding: Funding was provided by NIH T32CA009679 (to T.J.B.). K.A.R. receives research funding from Clovis Oncology, Bristol-Myers-Squibb, and GlaxoSmithKline. For T.J.B., none were declared. Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.

PY - 2021/12/27

Y1 - 2021/12/27

N2 - Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.

AB - Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.

KW - BRCA

KW - DNA damage repair

KW - homologous recombination repair

KW - pancreatic cancer

KW - PARP inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85122097411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122097411&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000554

DO - 10.1097/PPO.0000000000000554

M3 - Review article

C2 - 34904809

AN - SCOPUS:85122097411

SN - 1528-9117

VL - 27

SP - 465

EP - 475

JO - Cancer Journal

JF - Cancer Journal

IS - 6

ER -

PARP Inhibitors in Pancreatic Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this